Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Goldman Sachs Buy upgrade, citing growth potential from sovereign AI and customized software applications, has helped drive Palantir shares to fresh highs. Bulls are celebrating the momentum and speculating about a short squeeze, while bears warn that the valuation is stretched and the rally could reverse.

Modernas Nasdaq-100 inclusion and expected index-fund buying, alongside a reported NIH push to accelerate cancer vaccines, are driving attention; traders also point to the companys Merck-partnered personalized melanoma vaccine. Bulls welcome the momentum and oncology prospects, while skeptics argue the rally may be driven by index flows and short covering and question whether the valuation can hold.

SpaceXs planned acquisition of Grain Managements 800 MHz spectrum has fueled concern that Starlink will become a stronger competitor in satellite-to-phone connectivity, weighing on ASTS shares. Traders are split: bears see a threat to ASTSs position, while bulls argue SpaceXs push into wireless could strengthen ASTSs role as a satellite partner to carriers, whose spectrum access the CEO has highlighted.

Novavax is drawing attention around the Sanofi Phase 3 COVID-flu combination trial, whose EU authorization and potential milestone payment have bolstered interest in the partnership and Matrix-M platform. Traders also debate whether a Russian suspected-plague scare and broader vaccine-sector momentum amplified the rally, while many frame the move as a possible short squeeze and caution that the outbreak link is unverified.

GameStops strong advance toward a 52-week high and breakout momentum are driving attention, with traders anticipating a possible short or options-driven squeeze. Excitement over potential gamma effects and rumored Ryan Cohen or Roaring Kitty developments is countered by skepticism that the rally lacks a confirmed catalyst and could fade or face dilution.

SpaceXs agreement to acquire Grain Managements 800 MHz spectrum portfolio has stoked concern that Starlink Mobile could become a competitor to established wireless carriers, contributing to T-Mobiles sharp selloff. Traders are split between viewing the deal as a long-term threat and calling the reaction excessive given the infrastructure, capacity and time needed to build a competitive network.

A sharp Hims & Hers rally has revived breakout and short-covering chatter after months of choppy trading, though traders remain divided on whether the move can hold or will fade at resistance. Speculation about potential peptide access or regulatory changes is also cited as a possible catalyst, but no approval is confirmed.

Snowflakes stronger-than-expected quarterly results and raised outlook, with AI demand cited as boosting data-platform consumption, drove a sharp rally and continued focus on the stock. Traders are divided between expecting further gains and warning that the valuation is stretched, with some pointing to profit-taking after the earnings surge.

Mosaic is drawing attention after a steep selloff to multi-year lows, with traders pointing to weak results, high sulfur and other input costs, and phosphate production curtailments as pressure on margins. Some see fertilizer supply disruptions as a potential longer-term tailwind, but others question whether higher fertilizer prices can offset costs and weigh on farmer demand.

GPCR is drawing attention amid a steep selloff that traders say has hit obesity-biotech peers as well; discussion centers on speculation about institutional selling and concerns that alenigliprons efficacy, tolerability, and long Phase 3 timeline may struggle against competing obesity drugs. Some investors see the companys cash balance and pipeline as undervalued, while others remain cautious about the clinical and commercial outlook.